Italian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy

Infection

Volumn 37, Issue 3, 2009, Pages 270-282

  Antinori, A ^a   Ammassari, A ^a   Torti, C ^b   Marconi, P ^a   Andreoni, M ^c   Angarano, G ^d   Bonora, S ^e   Castagna, A ^f   Cauda, R ^g   Clerici, M ^h   D'Arminio Monforte, A ^h   De Luca, A ^g   Di Perri, G ^e   Galli, M ⁱ   Girardi, E ^a   Gori, A ^j   Lazzarin, A ^f   Lo Caputo, S ^k   Mazzotta, F ^k   Montella, F ^l   Mussini, C ^m   Perno, C F ^c   Puoti, M ^b   Rizzardini, G ⁱ   Rusconi, S ⁱ   Vullo, V ⁿ   Carosi, G ^b   more..

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e AMEDEO DI SAVOIA HOSPITAL   (Italy)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^l SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^m UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; FOLINIC ACID; PENTAMIDINE; PYRIMETHAMINE; RIFABUTIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; DISEASE COURSE; GENETIC RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABORATORY DIAGNOSIS; LABORATORY TEST; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT MONITORING; RISK FACTOR; AIDS RELATED COMPLEX; COMORBIDITY; CONFERENCE PAPER; DRUG ADMINISTRATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; PRACTICE GUIDELINE; STATISTICS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMORBIDITY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HIV; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC;

EID: 67650239791     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-8134-8     Document Type: Article

References (79)

1. S. Schwarcz L. Hsu J.W. Dilley L. Loeb K. Nelson S. Boyd 2006 Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS J Acquir Immune Defic Syndr 43 491 494
2. E. Girardi C.A. Sabin A.D. Monforte 2007 Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing J Acquir Immune Defic Syndr 46 S3 S8
3. M. Battegay U. Fluckiger B. Hirschel H. Furrer 2007 Late presentation of HIV-infected individuals Antivir Ther 12 841 851
4. E. Wood R.S. Hogg B. Yip P.R. Harrigan J.S. Montaner 2005 Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr 38 289 295
5. C.A. Sabin C.J. Smith M. Youle F.C. Lampe D.R. Bell D. Puradiredja M.C. Lipman S. Bhagani A.N. Phillips M.A. Johnson 2006 Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers AIDS 20 67 71
6. U.B. Dragsted A. Mocroft S. Vella J.P. Viard A.B. Hansen G. Panos D. Mercey L. Machala A. Horban J.D. Lundgren 2004 EuroSIDA study group: Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study J Infect Dis 190 148 155 (Pubitemid 38858415)
7. G.R. Kaufmann H. Furrer B. Ledergerber L. Perrin M. Opravil P. Vernazza M. Cavassini E. Bernasconi M. Rickenbach B. Hirschel M. Battegay 2005 Swiss HIV Cohort Study: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy Clin Infect Dis 41 361 372
8. G. Chene J.A. Sterne M. May D. Costagliola B. Ledergerber A.N. Phillips F. Dabis J. Lundgren A. D'Arminio Monforte F. de Wolf R. Hogg P. Reiss A. Justice C. Leport S. Staszewski J. Gill G. Fatkenheuer M.E. Egger 2003 Antiretroviral Therapy Cohort Collaboration: Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies Lancet 362 679 686
9. F.J. Palella Jr M. Deloria-Knoll J.S. Chmiel A.C. Moorman K.C. Wood A.E. Greenberg S.D. Holmberg 2003 HIV Outpatient Study Investigators: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata Ann Intern Med 138 620 626
10. Panel on antiretroviral guidelines for adults and adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 29 January 2008; pp 1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed: 16 July 2008.
11. Centers for Disease Control and Prevention: Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR recommendations and reports. December 18, 1992/41 (RR-17).
12. F.J. Palella Jr R.K. Baker A.C. Moorman J.S. Chmiel K.C. Wood J.T. Brooks S.D. Holmberg 2006 HIV Outpatient Study Investigators: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study J Acquir Immune Defic Syndr 43 27 34
13. A.N. Phillips J.D. Lundgren 2006 The CD4 lymphocyte count and risk of clinical progression Curr Opin HIV AIDS 1 43 49
14. P. Nunn R. Brindle L. Carpenter J. Odhiambo K. Wasunna R. Newnham W. Githui S. Gathua M. Omwega K. McAdam 1992 Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality Am Rev Respir Dis 146 849 854
15. P.E. Sax R. Islam R.P. Walensky E. Losina M.C. Weinstein S.J. Goldie S.N. Sadownik K.A. Freedberg 2005 Should resistance testing be performed for treatment-naïve HIV-infected patients? A costeffectiveness analysis Clin Infect Dis 41 1316 1323
16. Palmer S, Boltz V, Maldarelli F, Halvas E, Mellors J, Coffin J: New real-time PCR assay quantifies K103N NNRTI-resistant variant at a frequency as lowas 0.01%[abstract P36]. In: Programand abstracts of the National Cancer Institute third HIV drug resistance program symposium: antiviral drug resistance (Chantilly,VA, 8-11December 2002). National Cancer Institute, Bethesda 2002, pp 74.
17. G.J. Moyle A. Wildfire S. Mandalia H. Mayer J. Goodrich J. Whitcomb B.G. Gazzard 2005 Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection J Infect Dis 191 866 872
18. S. Mallal E. Phillips G. Carosi J.M. Molina C. Workman J. Tomazic E. Jägel-Guedes S. Rugina O. Kozyrev J.F. Cid P. Hay D. Nolan S. Hughes A. Hughes S. Ryan N. Fitch D. Thorborn A. Benbow 2008 PREDICT-1 Study Team: HLA-B*5701 screening for hypersensitivity to abacavir N Engl J Med 358 568 579
19. C.A. Benson J.E. Kaplan H. Masur A. Pau K.K. Holmes 2004 CDC, National Institutes of Health; Infectious Diseases Society of America Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/InfectiousDiseases Society of America 53 RR-15 1 112
20. I. Brock M. Ruhwald B. Lundgren H. Westh L.R. Mathiesen P. Ravn 2006 Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test Respir Res 7 56
21. R.T. Gandhi J. Spritzler E. Chan D.M. Asmuth B. Rodriguez T.C. Merigan M.S. Hirsch R.W. Shafer G.K. Robbins R.B. Pollard 2006 ACTG 384 Team: Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384 J Acquir Immune Defic Syndr 42 426 434
22. J. Robertson M. Meier J. Wall J. Ying C.J. Fichtenbaum 2006 Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy Clin Infect Dis 42 1639 1646
23. M.A. French P. Price S.F. Stone 2004 Immune restoration disease after antiretroviral therapy AIDS 18 1615 1627
24. B. Ledergerber M. Egger V. Erard R. Weber B. Hirschel H. Furrer M. Battegay P. Vernazza E. Bernasconi M. Opravil D. Kaufmann P. Sudre P. Francioli A. Telenti 1999 AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study JAMA 282 2220 2226
25. C. Smit R. Geskus S. Walker C. Sabin R. Coutinho K. Porter M. Prins 2006 CASCADE Collaboration: Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion AIDS 20 741 749
26. Jaen A, Esteve A, Montoliu A, Miro J, Podzamczer D, Tural C, Riera M, Segura F, Force L, Vilaro L, Garcia I, Masabeu A, Altes J, Sued O, Clotet B, Ferrer E, Casabona J, Piscis Study Group: When is the optimal moment to start HAART in HIV infected patients from PISCIS cohort study (Spain)? Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco, California. Abstract H-1059.
27. A. d'Arminio Monforte C.A. Sabin A. Phillips J. Sterne M. May A. Justice F. Dabis S. Grabar B. Ledergerber J. Gill P. Reiss M. Egger 2005 The Antiretroviral Therapy Cohort Collaboration: The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy Arch Intern Med 165 416 423
28. G. Carosi E. Quiros-Roldan C. Torti A. Antinori M. Bevilacqua R.C. Bonadonna P. Bonfanti A. Castagna R. Cauda A. d'Arminio-Monforte P. Di Gregorio G. Di Perri R. Esposito F. Fatuzzo C. Gervasoni C. Giannatasio G. Guaraldi A. Lazzarin C. S. Lo P. Maggi F. Mazzotta M. Moroni T. Prestileo R. Ranieri G. Rizzardini R. Russo M. Galli 2007 members of the Italian Cardiovascular Risk Guidelines Working Group: First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIVinfected patients in the ERA (2006) Infection 35 1 9
29. V. Miller A.N. Phillips B. Clotet A. Mocroft B. Ledergerber O. Kirk V. Ormaasen P. Gargalianos-Kakolyris S. Vella J.D. Lundgren 2002 Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts J Infect Dis 186 189 197
30. E. Wood R.S. Hogg B. Yip P.R. Harrigan J.S. Montaner 2004 Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence AIDS 18 2432 2434
31. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Kozal MJ, van den Berg-Wolf M, Henely C, Huppler-Hullsiek K, Schmetter B, Dehlinger M, for the CPCRA 058 Study Team and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA): Long-term clinical and immunologic outcomes are similar in HIV-infected persons randomized to NNRTI vs PI vs NNRTI + PI-based antiretroviral regimens as initial therapy: results of the CPCRA 058 FIRST study. Program and abstracts of the XVI International AIDS Conference; 13-18 August 2006, Toronto, Canada. Abstract TUAB0102.
32. F. Pulido J.R. Arribas J.M. Miro M.A. Costa J. Gonzalez R. Rubio J.M. Pena M. Torralba M. Lonca A. Lorenzo C. Cepeda J.J. Vazquez J.M. Gatell 2004 EfaVIP Cohort Study Group: Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviralnaïve patients with advanced HIV infection (EfaVIP 2 study) J Acquir Immune Defic Syndr 35 343 350
33. Riddler SA, Haubrich R, DiRienzo G, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Havlir D, Mellors JW, AIDS Clinical Trials Group 5142 Study Team: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection: ACTG 5142. Program and abstracts of the XVI International AIDS Conference; 13-18 August 2006, Toronto, Canada. Abstract THLB0204.
34. P. Barreiro V. Soriano E. Casas J. Gonzalez-Lahoz 2002 Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides AIDS 16 245 249
35. C.H. Olsen J. Gatell B. Ledergerber C. Katlama N. Friis-Moller J. Weber A. Horban S. Staszewski J.D. Lundgren A.N. Phillips 2005 EuroSIDA Study Group: Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen AIDS 19 319 330
36. C. Hicks M.S. King R.M. Gulick A.C. White Jr J.J. Eron Jr H.A. Kessler C. Benson K.R. King R.L. Murphy S.C. Brun 2004 Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatmentnaïve patients: 4 year follow-up study AIDS 18 775 779
37. Murphy R, da Silva B, McMillan F, Hicks C, Eron J, Wolfe P, Gulick R, Glesby M, Thompson M, Benson C, White AC, Albrecht M, Kessler H, Niemi K, King K, Calhoun D, King M, Hanna G, Brun S: Seven year follow-up of a lopinavir/ritonavir-based regimen in antiretroviral-naïve subjects. In: 10th European AIDS Conference. 17-20 November 2005. Dublin. Abstract PE7.9/3.
38. Eron J, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, Lackey P, Yau L, Sutherland-Phillips D, Wannamaker P, Shaefer M: The KLEAN study: fosamprenavir + ritonavir (FPV/r) versus lopinavir/ritonavir (LPV/r) in antiretroviral-naïve (ART naïve) HIV-1 infected adults over 48 weeks. Program and abstracts of the XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada. Abstract THLB0205.
39. Smith K, Weinberg W, DeJesus E, et al. Efficacy and safety of once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral-naïve HIV-infected patients: 24-week results from COL103952 (ALERT). Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy, 27-30 September 2006, San Francisco, CA. Abstract H-1670a.
40. Clumeck N, Van Lunzen J, Chiliade P, Clotet B, Vanden Abeele C, Lefebvre E, Vangeneugden T, Spinosa-Guzman S, DeMasi R: ARTEMIS - Efficacy and Safety of Lopinavir (BID vs QD) and Darunavir (QD) in Antiretroviral-naïve Patients. In: 11th European AIDS Conference, Madrid, 2007. Abstract LBPS7/5.
41. R.M. Gulick H.J. Ribaudo C.M. Shikuma C. Lalama B.R. Schackman W.A. Meyer 3rd E.P. Acosta J. Schouten K.E. Squires C.D. Pilcher R.L. Murphy S.L. Koletar M. Carlson R.C. Reichman B. Bastow K.L. Klingman D.R. Kuritzkes 2006 AIDS Clinical Trials Group (ACTG) A5095 Study Team: Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial JAMA 296 769 781
42. Delfraissy JF, Flandre P, Delaugerre C, Horban A, Girard PM, Rouzioux C, Norton M, Cohen-Codar I, NgoVan P, Chauvin JP: 48 Week analysis of LPV/r monotherpay compared to LPV/r + AZT/3TC in antiretroviral- naïve patients: MONARK trial. XVI International AIDS Conference, 13-18 Aug 2006, Toronto, Canada. Abstract THLB0202.
43. M.A. Boyd N.M. Dixit U. Siangphoe N.E. Buss M.P. Salgo J.M. Lange P. Phanuphak D.A. Cooper A.S. Perelson K. Ruxrungtham 2006 Viral decay dynamics in HIV-infected patients receiving ritonavirboosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012) J Infect Dis 194 1319 1322
44. A. Antinori A. Cozzi-Lepri A. Ammassari M.P. Trotta D. Nauwelaers R. Hoetelmans R. Murri S. Melzi P. Narciso P. Nasta M. Zaccarelli P. Santopadre J. Vecchiet C.M. Izzo A. Monforte 2004 AdICoNA Study Group: Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART Antivir Ther 9 291 296
45. D.R. Bangsberg E.P. Acosta R. Gupta D. Guzman E.D. Riley P.R. Harrigan N. Parkin S.G. Deeks 2006 Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness AIDS 20 223 231
46. E. Wood R.S. Hogg B. Yip D. Moore P.R. Harrigan J.S. Montaner 2006 Impact of baseline viral load and adherence on survival of HIVinfected adults with baseline CD4 cell counts > or = 200 cells/microl AIDS 20 111711 111723
47. T.R. Glass S. De Geest B. Hirschel M. Battegay H. Furrer M. Covassini P.L. Vernazza E. Bernasconi M. Rickenboch R. Weber H.C. Bucher 2008 Swiss HIV Cohort Study: Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients Antivir Ther 13 77 85
48. Zolopa A, Andersen J, Komarow L, Sanchez A, Suckow C, Sanne I, Hogg E, Powderly W, and ACTG A5164 Study Team: Immediate vs deferred ART in the setting of acute AIDS-related opportunistic infection: final results of a randomized strategy trial, ACTG A5164. In: 15th Conference on Retroviruses and Opportunistic Infections. Boston (MA) 3-6 February 2008 (Abstract 142).
49. J.H. Kempen D.A. Jabs L.A. Wilson J.P. Dunn S.K. West J. Tonascia 2003 Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome Clin Infect Dis 37 1365 1373 (Pubitemid 37433634)
50. A. Antinori D. Larussa A. Cingolani P. Lorenzini S. Bossolasco M.G. Finazzi M. Bongiovanni G. Guaraldi S. Grisetti B. Vigo B. Gigli A. Mariano E.R. Dalle Nogare M. De Marco F. Moretti P. Corsi N. Abrescia P. Rellecati A. Castagna C. Mussini A. Ammassari P. Cinque A. d'Arminio Monforte 2004 Italian Registry Investigative NeuroAIDS: Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy Clin Infect Dis 39 1681 1691
51. A. Morris R.M. Wachter J. Luce J. Turner L. Huang 2003 Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia AIDS 17 73 80
52. M. Wislez E. Bergot M. Antoine A. Parrot M.F. Carette C. Mayaud J. Cadranel 2001 Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia Am J Respir Crit Care Med 164 847 851
53. J.P. Spano D. Costagliola C. Katlama N. Mounier E. Oksenhendler D. Khayat 2008 AIDS-Related Malignancies: State of the Art and Therapeutic Challenges J Clin Oncol 26 4834 4842
54. A. Antinori A. Cingolani L. Alba A. Ammassari D. Serraino B.C. Ciancio F. Palmieri A. De Luca L.M. Larocca L. Ruco G. Ippolito R. Cauda 2001 Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy AIDS 15 1483 1491
55. C. Hoffmann E. Wolf G. Fatkenheuer T. Buhk A. Stoehr A. Plettenberg H.J. Stellbrink H. Jaeger U. Siebert H.A. Horst 2003 Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma AIDS 17 1521 1529
56. M. Simcock M. Blasko U. Karrer B. Bertisch M. Pless L. Blumer S. Vora J.O. Robinson E. Bernasconi B. Terziroli S. Moirandat-Rytz H. Furrer B. Hirschel P. Vernazza P. Sendi M. Rickenbach H.C. Bucher M. Battegay M.T. Koller 2007 Swiss HIV Cohort Study: Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study Antivir Ther 12 931 939
57. M.C. Cheung L. Pantanowitz B.J. Dezube 2005 AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy Oncologist 10 412 426
58. S. Sungkanuparph W. Manosuthi S. Kiertiburanakul A. Vibhagool 2006 Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand J Infect 52 188 194
59. S.D. Lawn L. Myer L.G. Bekker R. Wood 2007 Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa AIDS 21 335 341
60. D.M. Murdoch W.D. Venter C. Feldman A. Van Rie 2008 Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study AIDS 22 601 610
61. C. Mussini P. Pezzotti A. Antinori V. Borghi A. Monforte A. Govoni A. De Luca A. Ammassari N. Mongiardo M.C. Cerri A. Bedini C. Beltrami M.A. Ursitti T. Bini A. Cossarizza R. Esposito 2003 Changes in Opportunistic Prophylaxis (CIOP) Study Group: Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group Clin Infect Dis 36 645 651
62. C. Zellweger M. Opravil E. Bernasconi M. Cavassini H.C. Bucher V. Schiffer T. Wagels M. Flepp M. Rickenbach H. Furrer 2004 Swiss HIV Cohort Study: Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study AIDS 18 2047 2053
63. O. Kirk P. Reiss C. Uberti-Foppa M. Bickel J. Gerstoft C. Pradier F.W. Wit B. Ledergerber J.D. Lundgren H. Furrer 2002 European HIV Cohorts: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy Ann Intern Med 137 239 250
64. J.M. Miro J.C. Lopez D. Podzamczer J.M. Pena J.C. Alberdi E. Martinez P. Domingo J. Cosin X. Claramonte J.R. Arribas M. Santin E. Ribera 2006 GESIDA 04/98 Study Group: Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial Clin Infect Dis 43 79 89 (Pubitemid 43939080)
65. J. Berenguer J. Gonzalez F. Pulido B. Padilla J.L. Casado R. Rubio J.R. Arribas 2002 Madrid Group for the Study of Discontinuation of Secondary Prophylaxis in Patients with CMV Retinitis: Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy Clin Infect Dis 34 394 397
66. A. Vibhagool S. Sungkanuparph P. Mootsikapun P. Chetchotisakd S. Tansuphaswaswadikul C. Bowonwatanuwong A. Ingsathit 2003 Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study Clin Infect Dis 36 1329 1331
67. J.C. McArthur M.P. McDermott D. McClernon C. St Hillaire K. Conant K. Marder G. Schifitto O.A. Selnes N. Sacktor Y. Stern S.M. Albert K. Kieburtz J.A. de Marcaida B. Cohen L.G. Epstein 2004 Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy Arch Neurol 61 1687 1696
68. V. Tozzi P. Balestra S. Galgani P. Narciso A. Sampaolesi A. Antinori M. Giulianelli D. Serraino G. Ippolito 2001 Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years J Acquir Immune Defic Syndr 28 19 27
69. T.D. Parsons K.A. Tucker C.D. Hall W.T. Robertson J.J. Eron M.W. Fried K.R. Robertson 2006 Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection AIDS 20 1591 1595
70. G. Antonucci E. Girardi A. Cozzi-Lepri M.R. Capobianchi A. De Luca M. Puoti E. Petrelli G. Carnevale G. Rizzardini P.A. Grossi P. Vigano M.C. Moioli F. Carletti M. Solmone G. Ippolito A.D. Monforte 2005 HepaI.Co.N.A. Study Group, Italian Cohort naïve for Antiretrovirals Study Group: Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naïve HIVinfected individuals Clin Infect Dis 40 e101 e109
71. G. Schifitto K. Kieburtz M.P. McDermott J. McArthur K. Marder N. Sacktor D. Palumbo O. Selnes Y. Stern L. Epstein S. Albert 2001 Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes Neurology 56 415 418
72. C.M. Marra D. Lockhart J.R. Zunt M. Perrin R.W. Coombs A.C. Collier 2003 Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy Neurology 60 1388 1390
73. E.V. Capparelli D. Holland C. Okamoto B. Gragg J. Durelle J. Marquie-Beck G. van den Brande R. Ellis S. Letendre 2005 HNRC Group: Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV AIDS 19 949 952
74. A. Antinori C.F. Perno M.L. Giancola F. Forbici G. Ippolito R.M. Hoetelmans S.C. Piscitelli 2005 Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma Clin Infect Dis 41 1787 1793
75. J.A. Pineda M. Romero-Gomez F. Diaz-Garcia J.A. Giron-Gonzalez J.L. Montero J. Torre-Cisneros R.J. Andrade M. Gonzalez-Serrano J. Aguilar M. Aguilar-Guisado J.M. Navarro J. Salmeron F.J. Caballero-Granado J.A. Garcia-Garcia 2005 Grupo Andaluz para el Estudio de las Enfermedades Infecciosas; Grupo Andaluz para el Estudio del Higado: HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis Hepatology 41 779 789
76. D. Konopnicki A. Mocroft S. de Wit F. Antunes B. Ledergerber C. Katlama K. Zilmer S. Vella O. Kirk J.D. Lundgren 2005 EuroSIDA Group: Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort AIDS 19 593 601
77. M.S. Sulkowski S.H. Mehta M. Torbenson N.H. Afdhal L. Mirel R.D. Moore D.L. Thomas 2005 Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus AIDS 19 585 592
78. J. Sasadeusz J. Audsley A. Mijch R. Baden J. Caro H. Hunter G. Matthews M.A. McMahon S.A. Olender R.F. Siliciano S.R. Lewin C.L. Thio 2008 The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naïve patients AIDS. 22 947 955
79. M.S. Sulkowski S.H. Mehta R.E. Chaisson D.L. Thomas R.D. Moore 2004 Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir AIDS 18 2277 2284